These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 37357622)
1. Treatment of older patients with mantle cell lymphoma in the era of novel agents. Rozental A; Jim HSL; Extermann M Leuk Lymphoma; 2023 Sep; 64(9):1514-1526. PubMed ID: 37357622 [TBL] [Abstract][Full Text] [Related]
2. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438 [TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699 [TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102 [TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458 [TBL] [Abstract][Full Text] [Related]
11. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Dawar R; Hernandez-Ilizaliturri F Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454 [TBL] [Abstract][Full Text] [Related]
12. Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011 [TBL] [Abstract][Full Text] [Related]
13. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. Nazeef M; Kahl BS Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443 [TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436 [TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. Aurer I Curr Opin Oncol; 2019 Sep; 31(5):374-379. PubMed ID: 31233483 [TBL] [Abstract][Full Text] [Related]
16. Treatment strategies in mantle cell lymphoma. Maddocks K; Blum KA Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613 [TBL] [Abstract][Full Text] [Related]
17. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350 [TBL] [Abstract][Full Text] [Related]
18. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease. Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332 [TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667 [TBL] [Abstract][Full Text] [Related]
20. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. Di M; Huntington SF; Olszewski AJ Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]